Cefoperazone versus combination antibiotic therapy of hospital-acquired pneumonia

https://doi.org/10.1016/0002-9343(88)90010-1Get rights and content

Abstract

Cefoperazone monotherapy was compared with combination antibiotic therapy in a randomized prospective evaluation of patients with hospital-acquired pneumonia. Cefoperazone was as effective as either clindamycin/gentamicin or cefazolin/gentamicin (cure rate: 45 of 52 cefoperazone-treated patients [87 percent], versus 44 of 61 combination-therapy patients [72 percent], p = 0.069). With the exception of hypoprothrombinemia in those patients who did not receive prophylactic vitamin K, there was no difference in the incidence of side effects. In addition, no difference was noted in the incidence of superinfections or secondary pneumonias. When antibiotic costs, administration costs, and laboratory costs were considered, cefoperazone monotherapy was the least expensive antibiotic regimen. Cefoperazone is a suitable alternative to combination antibiotic therapy for the treatment of hospital-acquired pneumonia.

References (27)

  • A Verghese et al.

    Bacterial pneumonia in the elderly

    Medicine (Baltimore)

    (1983)
  • M Davidson et al.

    Bacteriologic diagnosis of acute pneumonia

  • JG Bartlett et al.

    Bacteriology of hospital-acquired pneumonia

    Arch Intern Med

    (1986)
  • Cited by (43)

    • Consensus document on controversial issues for the treatment of hospital-associated pneumonia

      2010, International Journal of Infectious Diseases
      Citation Excerpt :

      The former approach should be used if patients are likely to be infected with MDR pathogens. In the guidelines from Brazil and Argentina,31 on the basis of an analysis of a few studies,44–46 the authors are convinced that monotherapy in the treatment of HAP without MDR strains reduces costs and unnecessary exposure to antibiotics . The more recent guidelines of the British Society for Antimicrobial Chemotherapy (BSAC)32 revised the results of 16 RCTs enrolling patients with HAP (but not exclusively) and comparing patients receiving monotherapy with combination therapy with an aminoglycoside.42,43,45,47–58

    • International conference for the development of consensus on the diagnosis and treatment of ventilator-associated pneumonia

      2001, Chest
      Citation Excerpt :

      There was general agreement that the number of previous days of hospitalization was a more important factor than the number of previous days of ventilation and that other factors concerning the individual patient must be considered before monotherapy is chosen, such as the absence of structural lung disease, the absence of corticotherapy, the absence of immunosuppression, and the absence of antibiotherapy in the last 3 months. Generally, antibiotic monotherapy has shown success rates and rates of superinfections and colonization by multiresistant microorganisms that are similar to those for combination therapy.81828384858687 But other studies have demonstrated that patients with severe infections by P aeruginosa and multiresistant Klebsiella spp or Acinetobacter spp are better treated with combination antibiotherapy, such as antipseudomonal β-lactam plus aminoglycoside.8889

    • An approach to empiric therapy of nosocomial pneumonia

      1994, Medical Clinics of North America
    View all citing articles on Scopus

    This work was presented in part at the Fourteenth International Conference of Antibiotic Agents and Chemotherapy, Kyoto, Japan, June 26, 1985, and was supported in part by a grant from Pfizer Pharmaceuticals.

    View full text